Plus Therapeutics, Inc. (NASDAQ:PSTV) Stock Rated “Hold” by Sell-Side Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been given an average rating of “Hold” by the six analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $51.75.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Citadel Advisors LLC purchased a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,597 shares of the company’s stock, valued at approximately $112,000. Citadel Advisors LLC owned 0.37% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Price Performance

Plus Therapeutics stock opened at $1.88 on Friday. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.42. The business has a 50 day moving average of $2.50 and a 200-day moving average of $4.08. The company has a market capitalization of $12.94 million, a P/E ratio of -0.82 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.43). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.11 million. Equities analysts anticipate that Plus Therapeutics will post -3.76 EPS for the current year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s approach combines radioactive isotopes with nanoparticle-based drug-delivery technology designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nano liposomes, also known as 186RNL. The treatment is being evaluated for recurrent glioblastoma and leptomeningeal metastases, cancers affecting the brain and spinal cord.